{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "20058135",
  "DateCompleted": {
    "Year": "2010",
    "Month": "03",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2010",
        "Month": "01",
        "Day": "09"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s11748-009-0498-x"
    ],
    "Journal": {
      "ISSN": "1863-6713",
      "JournalIssue": {
        "Volume": "58",
        "Issue": "1",
        "PubDate": {
          "Year": "2010",
          "Month": "Jan"
        }
      },
      "Title": "General thoracic and cardiovascular surgery",
      "ISOAbbreviation": "Gen Thorac Cardiovasc Surg"
    },
    "ArticleTitle": "UFT and S-1 for treatment of primary lung cancer.",
    "Pagination": {
      "StartPage": "3",
      "EndPage": "13",
      "MedlinePgn": "3-13"
    },
    "Abstract": {
      "AbstractText": [
        "UFT and S-1 are oral 5-fluorouracil (5-FU) derivative drugs containing an inhibitor of dihydropyrimidine dehydrogenase (DPD); they are defined as DPD-inhibitory fluoropyrimidine (DIF). Because DPD is the key enzyme of 5-FU degradation, 5-FU is not active in primary lung cancers with high DPD activity, which causes rapid degradation of 5-FU. Thus, theoretically, a DIF can overcome a cancer's resistance to 5-FU through inhibiting the enzyme activity of DPD, with the result that 5-FU may be active in primary lung cancer. In fact, UFT has proved to be effective in a postoperative adjuvant setting for early non-small-cell lung cancer (NSCLC) in several randomized controlled studies (RCTs). S-1, in which a more potent DPD inhibitor is combined, is active in advanced NSCLC regardless of the histological cell subtype, and its clinical efficacy in first-line therapy for unresectable advanced disease as well as in postoperative adjuvant therapy for resected disease is now being examined in a variety of RCTs. In the present review, the mechanism of action of UFT and S-1 as well as clinical evidence regarding their use in the treatment of NSCLC are summarized."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya 660-8501, Japan. ftanaka@hyo-med.ac.jp"
          }
        ],
        "LastName": "Tanaka",
        "ForeName": "Fumihiro",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wada",
        "ForeName": "Hiromi",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Fukushima",
        "ForeName": "Masakazu",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Japan",
    "MedlineTA": "Gen Thorac Cardiovasc Surg",
    "NlmUniqueID": "101303952",
    "ISSNLinking": "1863-6705"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Drug Combinations"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Enzyme Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "UFT(R) drug"
    },
    {
      "RegistryNumber": "150863-82-4",
      "NameOfSubstance": "S 1 (combination)"
    },
    {
      "RegistryNumber": "1548R74NSZ",
      "NameOfSubstance": "Tegafur"
    },
    {
      "RegistryNumber": "56HH86ZVCT",
      "NameOfSubstance": "Uracil"
    },
    {
      "RegistryNumber": "5VT6420TIG",
      "NameOfSubstance": "Oxonic Acid"
    },
    {
      "RegistryNumber": "EC 1.3.1.2",
      "NameOfSubstance": "Dihydrouracil Dehydrogenase (NADP)"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Oral"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "enzymology",
        "mortality",
        "pathology"
      ],
      "DescriptorName": "Carcinoma, Non-Small-Cell Lung"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chemotherapy, Adjuvant"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors"
      ],
      "DescriptorName": "Dihydrouracil Dehydrogenase (NADP)"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Combinations"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Resistance, Neoplasm"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Enzyme Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Evidence-Based Medicine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "enzymology",
        "mortality",
        "pathology"
      ],
      "DescriptorName": "Lung Neoplasms"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Oxonic Acid"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Radiotherapy, Adjuvant"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Tegafur"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Uracil"
    }
  ],
  "NumberOfReferences": "45"
}